Rituximab (Rituxan®) is a monoclonal antibody used to treat Non-Hodgkins Lymphoma (NHL). It targets the CD20 marker on B-cells from which most NHL develops.
Sally Church on Pharma Strategy Blog asks why do some patients develop resistance to rituximab, while others do not?
The answer according to recent research reviewed by Sally is that some patients develop C-terminal deletion mutations of CD20 that are part of the mechanism that causes resistance to rituximab in Non-Hodgkins Lymphoma (NHL).
As Sally points out in her blog post, understanding rituximab resistance in lymphoma can help identify patients who need to change treatments earlier. It may also lead to new product development opportunities e.g. targeting a different molecule such as CD22.